Lexicon Pharmaceuticals Supports MGFA's Launch of MG Lexicon for Myasthenia Gravis Patients

### Empowering Patients: The Launch of the MG Lexicon

The Myasthenia Gravis Foundation of America (MGFA) recently introduces the MG Lexicon, a pioneering digital resource aimed at enhancing communication between patients and healthcare professionals regarding myasthenia gravis (MG). This rare autoimmune neuromuscular disorder affects an estimated 90,000 to 100,000 individuals in the United States, leading to debilitating symptoms such as extreme fatigue and muscle weakness. The MG Lexicon, unveiled on December 5, 2025, seeks to bridge the knowledge gap between patients and medical experts by demystifying complex medical jargon associated with the condition. By providing clear definitions and explanations of terms relevant to diagnosing and managing MG, the lexicon empowers patients to engage more effectively in their healthcare discussions.

The development of the MG Lexicon results from extensive collaboration among patients, medical professionals, researchers, and industry partners. This initiative culminated in a series of stakeholder meetings held in Boston in 2024, where insights and feedback from the MG community were integrated into the resource. The lexicon is not just a glossary; it represents a concerted effort to improve the quality of care for MG patients by fostering informed conversations around symptoms, treatment options, and management strategies. By enabling patients to articulate their needs and experiences, the MG Lexicon aims to enhance the patient-provider relationship, ultimately leading to better health outcomes and a higher quality of life for those affected by the disease.

The MGFA’s commitment to the MG community extends beyond the lexicon. The organization actively funds research initiatives to discover more effective treatments and provides educational resources and support programs tailored to the needs of MG patients. As the MG Lexicon is made accessible through the MGFA’s website, it stands as a critical tool for individuals living with myasthenia gravis, helping to navigate the complexities of their condition while fostering a sense of empowerment and agency in their healthcare journey.

In addition to the launch of the MG Lexicon, the MGFA encourages ongoing communication with stakeholders, including patients and healthcare providers. Michael Antonellis, Vice President of Global Marketing & Communications, and Kate Stober, National Director of Digital and Content Marketing, are available for inquiries, reflecting the organization's commitment to being a resource for the MG community. This initiative represents a significant step forward in addressing the challenges faced by patients and underscores the importance of clear communication in managing chronic health conditions.